All In Biotech

Drug Trial Radar · NCT04483960

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial

A Multi-centre Randomised Adaptive Platform Clinical Trial to Assess Clinical, Virological and Immunological Outcomes in Patients With SARS-CoV-2 Infection (COVID-19)

Last checked: Nov 20, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 2,200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,200

Planned (sponsor's estimate)

Start

Jul 28, 2020

Primary completion

Jul 25, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
University of MelbourneAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Peter Doherty Institute for Infection and Immunity; Australasian Society for Infectious Diseases; Hunter Medical Research Institute; Aotearoa Clinical Trials; Australian and New Zealand Intensive Care Research Centre
First posted
Jul 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An International Multi-Centre Randomised Adaptive Platform Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients with SARS-CoV-2 Infection (COVID-19).

Conditions

  • SARS-CoV-2 Infection (COVID-19)

Interventions

  • (Arm Closed) Nafamostat MesilateDrug

    Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.

  • (Arm Closed) EnoxaparinDrug

    Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site. The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h.

  • (Arm Closed) DalteparinDrug

    Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site. The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h.

  • (Arm Closed) TinzaparinDrug

    Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site. The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia).

  • (Arm Never Opened) Hyperimmune globulinBiological

    2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation. Three vials will have approximately 10500 AU of neutralising antibodies, equivalent to approximately 200mL of convalescent plasma

  • Nirmatrelvir-RitonavirDrug

    The dose of nirmatrelvir-ritonavir is dependent on renal function. Participants will receive 100mg BD of Ritonavir and either 150mg BD (if eGFR 30-59 mL/min/1.73m2) or 300mg BD (eGFR = 60 mL/min/1.73m2) of Nirmatrelvir. Investigators are advised to consider withholding treatment if participant's eGFR \< 30 mL/min/1.73m2.

  • RemdesivirDrug

    The dose of intravenous remdesivir is 200 mg on day 1 followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first. Remdesivir will be administered as an intravenous infusion via a central or peripheral venous catheter over a 30-120 minute period, as per local practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A hierarchical ordinal scale that is a composite of mortality during the acute hospital admission and the duration of organ failure support while admitted to an ICU up until the end of study day 21.Time frame: Day 21

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Blacktown Hospital

    Blacktown, New South Wales, Australia

  • Campbelltown Hospital

    Campbelltown, New South Wales, Australia

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • John Hunter Hospital

    New Lambton Heights, New South Wales, Australia

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Wagga Wagga Base Hospital

    Wagga Wagga, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Wollongong Hospital

    Wollongong, New South Wales, Australia

  • Royal Darwin Hospital

    Tiwi, Northern Territory, Australia

  • The Prince Charles Hospital

    Chermside, Queensland, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Lyell McEwin Hospital

    Elizabeth Vale, South Australia, Australia

  • Ballarat Health Services

    Ballarat Central, Victoria, Australia

  • Eastern Health (Box Hill Hospital)

    Box Hill, Victoria, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Northern Health

    Epping, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Western Health

    St Albans, Victoria, Australia

  • West Gippsland Hospital

    Warragul, Victoria, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.